Literature DB >> 17434350

Orbital exenteration for advanced periorbital skin cancers: 20 years experience.

Reza S Nassab1, Sunil S Thomas, Douglas Murray.   

Abstract

PURPOSE: Orbital exenteration is a disfiguring procedure that results in a significant deformity which poses a reconstructive challenge, especially in elderly patients with significant comorbidities. We reviewed our experience of orbital exenteration.
METHODS: A retrospective analysis was conducted identifying all patients undergoing orbital exenteration over a 20-year period. Patient demographics, tumour characteristics and reconstructive techniques used were recorded.
RESULTS: Thirty-two patients were treated by orbital exenteration. The majority of these were for basal cell carcinomas (53%). Most patients (62.5%) were ASA grade II or more. Reconstructive techniques included split skin grafting (63%), forehead (25%), scalp (6%) and cervicofacial (6%) flaps. Following reconstruction of the exenterated orbit, 29 patients had a prosthesis. Twenty-six of these rated their final result with their definitive prosthesis as good.
CONCLUSIONS: Though there are various options available for reconstruction after orbital exenteration, a split skin graft and orbital prosthesis provide a simple solution for a very difficult problem of advanced periorbital skin cancer in the elderly population with significant comorbidities. The final outcome is comparable to that of more complex flap reconstruction with comparable satisfaction rates.

Entities:  

Mesh:

Year:  2007        PMID: 17434350     DOI: 10.1016/j.bjps.2007.02.012

Source DB:  PubMed          Journal:  J Plast Reconstr Aesthet Surg        ISSN: 1748-6815            Impact factor:   2.740


  18 in total

Review 1.  Prosthetic Reconstruction of Orbital Defects.

Authors:  Aurora Vincent; Scott Kohlert; Sameep Kadakia; Raja Sawhney; Yadranko Ducic
Journal:  Semin Plast Surg       Date:  2019-04-26       Impact factor: 2.314

Review 2.  Post-operative orbital imaging: a focus on implants and prosthetic devices.

Authors:  Ashok Adams; Kshitij Mankad; Cornelia Poitelea; David H Verity; Indran Davagnanam
Journal:  Neuroradiology       Date:  2014-08-07       Impact factor: 2.804

3.  Automated Noncontact Facial Topography Mapping, 3-Dimensional Printing, and Silicone Casting of Orbital Prosthesis.

Authors:  Ernesto H Weisson; Mauro Fittipaldi; Carlos A Concepcion; Daniel Pelaez; Landon Grace; David T Tse
Journal:  Am J Ophthalmol       Date:  2020-07-22       Impact factor: 5.258

4.  Surgical resection of invasive adenoid cystic carcinoma of the lacrimal gland and wound closure using a vertical rectus abdominis myocutaneous free flap.

Authors:  João Paulo Andrade; Sergio Figueiredo; Julio Matias; Ana Catarina Almeida
Journal:  BMJ Case Rep       Date:  2016-09-19

5.  Review of orbital exenterations in Korle-Bu teaching hospital.

Authors:  E Ackuaku-Dogbe
Journal:  Ghana Med J       Date:  2011-06

6.  Orbital exenteration for advanced periorbital non-melanoma skin cancer: prognostic factors and survival.

Authors:  R C Gerring; C T Ott; J M Curry; Z B Sargi; S T Wester
Journal:  Eye (Lond)       Date:  2016-10-21       Impact factor: 3.775

7.  Indications for destructive eye surgeries among adults in a tertiary eye care center in North CENTRAL Nigeria.

Authors:  O P Odugbo; P D Wade; O J Samuel; C D Mpyet
Journal:  J West Afr Coll Surg       Date:  2015 Apr-Jun

8.  Orbital exenteration in elderly patients: personal experience.

Authors:  A Croce; A Moretti; L D'Agostino; P Zingariello
Journal:  Acta Otorhinolaryngol Ital       Date:  2008-08       Impact factor: 2.124

9.  Clinicopathological profile of orbital exenteration: 14 years of experience from a tertiary eye care center in South India.

Authors:  Mohammad Javed Ali; Aditi Pujari; Tarjani Vivek Dave; Swathi Kaliki; Milind N Naik
Journal:  Int Ophthalmol       Date:  2015-08-07       Impact factor: 2.031

Review 10.  Management of high-risk and advanced basal cell carcinoma.

Authors:  S Puig; A Berrocal
Journal:  Clin Transl Oncol       Date:  2015-02-03       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.